Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
A Phase 2 Study to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
Sponsor: Thirty Respiratory Limited
Terminated
Decision was made by the sponsor not to progress to Stage 2
Other terminated trials from Thirty Respiratory Limited
More terminations from Thirty Respiratory Limited
This PHASE2 trial investigates Rifampicin Susceptible Pulmonary Tuberculosis and is currently terminated or withdrawn. Thirty Respiratory Limited leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Aug 2025 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Dec 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Oct 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Thirty Respiratory Limited
For direct contact, visit the study record on ClinicalTrials.gov .